TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL BIOSIMILAR BEVACIZUMAB, BY PRODUCT
6.1. Overview
6.2. Avastin
6.3. Mvasi
6.4. Zirabev
6.5. Aybintio
6.6. Other clinical trial products
7. GLOBAL BIOSIMILAR BEVACIZUMAB, BY APPLICATION
7.1. Overview
7.2. Colorectal cancer
7.3. Non-small cell lung cancer
7.4. Glioblastoma
7.5. Renal cell carcinoma
7.6. Cervical cancer
7.7. Ovarian cancer
8. GLOBAL BIOSIMILAR BEVACIZUMAB, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital pharmacy
8.3. Online pharmacy
8.4. Retail Pharmacy
8.5. Other Direct Distribution Channels
9. GLOBAL BIOSIMILAR BEVACIZUMAB, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Biosimilar Bevacizumab,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Biosimilar Bevacizumab,
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Services Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. Amgen
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. ARYOGEN
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Pharmed
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Biothera
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Centus Biotherapeutics
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Henlius Biotech
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. INNOVENT BIOLOGICS
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Mylan
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. MAbxience
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Outlook Therapeutics
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Pfizer
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Products Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Prestige Biopharma
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Products Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Roche
11.14.1. Company Overview
11.14.2. Financial Overview
11.14.3. Products Offered
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Samsung Bio
11.15.1. Company Overview
11.15.2. Financial Overview
11.15.3. Products Offered
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. TOT Biopharm
11.16.1. Company Overview
11.16.2. Financial Overview
11.16.3. Products Offered
11.16.4. Key Developments
11.16.5. SWOT Analysis
11.16.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL BIOSIMILAR BEVACIZUMAB, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL BIOSIMILAR BEVACIZUMAB, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL BIOSIMILAR BEVACIZUMAB, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL BIOSIMILAR BEVACIZUMAB, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL BIOSIMILAR BEVACIZUMAB, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 10 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 11 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 12 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 13 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 11 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 16 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 17 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 28 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 29 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 31 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 32 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOSIMILAR BEVACIZUMAB
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOSIMILAR BEVACIZUMAB
FIGURE 4 GLOBAL BIOSIMILAR BEVACIZUMAB, SHARE (%), BY PRODUCT, 2023
FIGURE 5 GLOBAL BIOSIMILAR BEVACIZUMAB, SHARE (%), BY APPLICATION, 2023
FIGURE 6 GLOBAL BIOSIMILAR BEVACIZUMAB, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 7 GLOBAL BIOSIMILAR BEVACIZUMAB, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL BIOSIMILAR BEVACIZUMAB: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 AMGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 AMGEN: SWOT ANALYSIS
FIGURE 15 ARYOGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 ARYOGEN: SWOT ANALYSIS
FIGURE 17 PHARMED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 PHARMED: SWOT ANALYSIS
FIGURE 19 BIOTHERA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 BIOTHERA: SWOT ANALYSIS
FIGURE 21 BOEHRINGER INGELHEIM.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 BOEHRINGER INGELHEIM.: SWOT ANALYSIS
FIGURE 23 CENTUS BIOTHERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 CENTUS BIOTHERAPEUTICS: SWOT ANALYSIS
FIGURE 25 HENLIUS BIOTECH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 HENLIUS BIOTECH: SWOT ANALYSIS
FIGURE 27 INNOVENT BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 INNOVENT BIOLOGICS: SWOT ANALYSIS
FIGURE 29 MYLAN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 MYLAN: SWOT ANALYSIS
FIGURE 31 MABXIENCE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 MABXIENCE: SWOT ANALYSIS
FIGURE 33 OUTLOOK THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 OUTLOOK THERAPEUTICS: SWOT ANALYSIS
FIGURE 35 PFIZER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 PFIZER: SWOT ANALYSIS
FIGURE 37 PRESTIGE BIOPHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 PRESTIGE BIOPHARMA: SWOT ANALYSIS
FIGURE 39 ROCHE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 ROCHE: SWOT ANALYSIS
FIGURE 41 SAMSUNG BIO: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 SAMSUNG BIO: SWOT ANALYSIS
FIGURE 43 TOT BIOPHARM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 TOT BIOPHARM: SWOT ANALYSIS
